[Clinical Study of Percutaneous Radiofrequency Ablation for Small Renal Tumor]

Hinyokika Kiyo. 2016 Oct;62(10):509-514. doi: 10.14989/ActaUrolJap_62_10_509.
[Article in Japanese]

Abstract

Percutaneous radiofrequency ablation (PRFA) has been applied as an option of minimally invasive treatment for small renal tumor. We retrospectively evaluated 5 patients with small renal tumor for whom PRFA was performed at our hospital. The average age was 69.6 years (range 45-86), average tumor diameter 20.0 mm (8-34), average preoperative glomerular filtration rate (eGFR) 66.8 ml/min/1.73m2 (42. 1-93.2), and follow-up period was 23.4 months (8-34). There were two minor complications (grade 1), including perirenal hematoma and pain at the probe insertion site in each patient. One patient had local recurrence 22 months after PRFA and the additional PRFA will be performed. PRFA could be a feasible, safe and effective therapy for small renal tumor.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carcinoma, Renal Cell / diagnostic imaging
  • Carcinoma, Renal Cell / surgery*
  • Catheter Ablation*
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Kidney Neoplasms / diagnostic imaging
  • Kidney Neoplasms / surgery*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Tomography, X-Ray Computed
  • Treatment Outcome